Eris Q1: consolidated PAT ₹143 Cr, up ~15% YoY on 13% revenue growth; margins softer as guided

Eris Lifesciences opened FY27 with a steady, on-plan quarter. Consolidated revenue from operations rose ~13% YoY to ₹873.25 Cr (Q1 FY26: ₹773.00 Cr) and net profit climbed ~14.6% to ₹143.32 Cr (₹142.39 Cr attributable to owners), with EPS at ₹10.28 versus ₹8.66 a year ago. There were no exceptional items this quarter on either side of the YoY comparison, so reported growth is also the underlying growth — a clean double-digit print rather than a flattered one. The headline QoQ decline (PAT down ~49% from Q4 FY26's ₹279.10 Cr) is an accounting artifact, not an operating one: Q4 carried a roughly ₹132 Cr consolidated deferred-tax write-back (total tax was negative that quarter) tied to remeasurement at the revised tax rate. Stripped of that, sequential revenue actually grew ~15% and the operating trend is intact. The margin story is the one to watch: disclosed operating margin eased to 25.94% from 27.02% a year ago, and EBITDA margin softened to ~34% from ~36%, sitting on higher employee costs (₹153.42 Cr) and other expenses (₹184.36 Cr) — the launch-related spend management flagged. NPM held roughly flat YoY at 16.41% (vs 16.18%). This maps directly onto guidance: on the Q4 call management guided FY27 consolidated EBITDA margin ~36% with H1 explicitly softer on launch expenses and improvement pushed to H2 via insourced manufacturing and new launches — and that is exactly the shape of this print. No formal quarterly consensus was available (results dropped the same day as the board meeting), so there is no street beat/miss to score against. Alongside results, the board re-appointed Kiran J. Mehta & Co. as cost auditors for FY27; the ₹7.21 interim dividend was declared earlier on May 20. Standalone tells a different, smaller-entity story (PAT ₹48.30 Cr on ₹443.99 Cr revenue) because most operations now sit in subsidiaries — the consolidated basis is the right read.